Can Immune-Calming cells tame multiple sclerosis?

NCT ID NCT04530318

Ongoing Disease control Sponsor: Judit Pich Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether infusions of special immune cells (tolerogenic dendritic cells) can reduce brain lesions and relapses in people with relapsing-remitting multiple sclerosis. The 45 participants also take standard MS drugs. The study aims to see if this cell therapy is safe and effective at controlling disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tolerogenic dendritic cells (TolDec)
What this could lead to: If it works, this could point toward a way to calm the immune system and reduce MS relapses without strong side effects.
What could go wrong: This is a small Phase 2 trial, so results may not be conclusive. The treatment is still experimental, and there is a risk of side effects or no benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING-REMITTING MULTIPLE SCLEROSIS

Contacts and locations

Locations

Hospital Clínic de Barcelona

Barcelona, 08036, Spain
Hospital Moisés Broggi

L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain
Hospital de Sant Pau

Barcelona, Spain
Hospital del Mar

Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.